SPS
PHAT icon

Susquehanna Portfolio Strategies’s Phathom Pharmaceuticals PHAT Stock Holding History

Susquehanna Portfolio Strategies’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-267,962
Closed -$2.98M – 1028
2026
Q1 		$2.98M Hold
267,962
– – 0.04% 402
2025
Q4 		$4.45M Hold
267,962
– – 0.07% 326
2025
Q3 		$3.15M Hold
267,962
– – 0.05% 405
2025
Q2 		$2.57M Buy
+267,962
New +$1.48M 0.06% 323

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GKIM
GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Susquehanna Portfolio Strategies's PHAT Position: Q2 2026 in Review

Susquehanna Portfolio Strategies sold out of Phathom Pharmaceuticals (PHAT) in Q2 2026, closing a stake of 267,962 shares — an estimated $2.98M sold.

Susquehanna Portfolio Strategies first reported a position in PHAT in Q2 2025 and held it in 4 quarters. The position peaked at $4.45M in Q4 2025. 161 funds tracked by Wall St. Rank hold PHAT as of Q2 2026.

  • Susquehanna Portfolio Strategies reported no remaining Phathom Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Susquehanna Portfolio Strategies sold 267,962 Phathom Pharmaceuticals shares in Q2 2026, an estimated $2.98M.
  • Susquehanna Portfolio Strategies first reported a position in Phathom Pharmaceuticals in Q2 2025 and held it in 4 quarters.
  • Susquehanna Portfolio Strategies's Phathom Pharmaceuticals position peaked at $4.45M in Q4 2025.
  • 161 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2026.

Based on Susquehanna Portfolio Strategies's 13F filing for Q2 2026, filed 14 Aug 2026.